相关临床试验
868
69 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1955
进行中（未招募）
30
3.5%
已完成
563
64.9%
Enrolling By Invitation
8
0.9%
No Longer Available
1
0.1%
尚未招募
31
3.6%
招募中
130
15.0%
暂停
3
0.3%
终止
63
7.3%
Unknown
1
0.1%
撤回
38
4.4%
暂无批准数据
- The University of Alabama at Birmingham ranked No. 42 and the Medical University of South Carolina ranked No. 44 out of 303 leading U.S. biomedical research institutions in the inaugural 2026 Cure Innovation Index. - The Cure Innovation Index is the first national, data-driven platform evaluating how effectively institutions convert scientific discovery into therapies, companies, and measurable health outcomes across 25 indicators. - UAB demonstrated particular strength in market translation and entrepreneurial readiness, while MUSC earned "Excellent" ratings in cutting-edge science, facilities and equipment, faculty engagement, and industry connections. - Both institutions have made significant investments in innovation infrastructure, including startup incubators, venture funds, and technology transfer programs to accelerate the path from discovery to patient impact.
- Researchers at the Medical University of South Carolina have developed Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a breakthrough treatment that helps patients recover from severe depression in days rather than months. - SAINT uses personalized MRI-guided magnetic stimulation to target specific brain circuits, delivering 10 treatment sessions daily over five days, with many patients meeting remission criteria in just two-and-a-half days. - The therapy addresses critical gaps in depression care, where traditional antidepressant effectiveness drops from 30% for first medications to just 7% by the fourth attempt. - SAINT is already available at MUSC and covered by Medicare and Blue Cross Blue Shield of South Carolina, representing a potential paradigm shift in mental health treatment.
- Tirzepatide, the active ingredient in Mounjaro, reduced voluntary alcohol consumption by more than half in animal models and prevented relapse-like drinking behaviors. - The dual GIP/GLP-1 receptor agonist appears to work by attenuating alcohol-induced dopamine effects in the brain's reward system, particularly in the lateral septum region. - Researchers identified changes in histone-related proteins in the lateral septum, suggesting potential long-term biological mechanisms underlying the drug's effects on addiction pathways. - The findings support further investigation of tirzepatide as a potential treatment for alcohol use disorder, leveraging its established clinical safety profile from diabetes and obesity applications.
- A phase 2 randomized controlled trial involving 174 participants found that varenicline, a smoking cessation medication, significantly reduced cannabis use in men with cannabis use disorder but showed no effect in women. - Men receiving varenicline averaged 7.9 cannabis sessions per week during treatment compared to over 12 sessions in the placebo group, while women showed no significant difference between treatment groups. - The study reveals important gender differences in treatment response, with women on varenicline experiencing higher withdrawal, craving, and anxiety scores along with lower medication adherence. - Researchers plan to conduct larger studies with more women participants to better understand the sex-specific treatment outcomes for this growing clinical problem.
- Magnus Medical has enrolled the first patient at UMass Chan Medical School in a $11.6 million Department of Defense-funded pivotal trial evaluating SAINT neuromodulation therapy for postpartum depression. - The randomized controlled trial will enroll up to 192 women aged 18-45 with major depressive episodes with peripartum onset across four leading research institutions. - SAINT therapy uses brain imaging to deliver personalized magnetic stimulation over five days, with previous studies showing 79% remission rates in treatment-resistant major depression in an average of 2.6 days. - The FDA-cleared, non-invasive treatment offers a drug-free alternative for the approximately 500,000 women affected by postpartum depression annually in the United States.
- Luspatercept doubled transfusion independence rates compared to erythropoietin-stimulating agents in the phase 3 COMMANDS trial, achieving 60% versus 35% response rates in low-risk myelodysplastic syndromes. - The survival benefit emerged after three years of treatment, with luspatercept showing superior overall survival compared to ESA in a piecewise analysis at 36 months or longer. - Duration of transfusion independence was significantly longer with luspatercept, particularly benefiting patients with SF3B1 mutations who achieved 70% response rates versus 33% with ESA. - The survival advantage appears linked to sustained transfusion independence rather than disease modification, potentially reducing cardiovascular mortality in this elderly patient population.
- The Medical University of South Carolina is initiating a clinical trial to treat triple-negative breast cancer patients with heart disease using three drugs instead of the standard five-drug regimen. - The study aims to address the challenge that Adriamycin, a key component of standard treatment, cannot be used in patients with heart conditions due to cardiomyopathy risks. - The trial will enroll 43 patients over two years, with treatment response assessed via MRI after 12 weeks of weekly drug administration. - Early success has been demonstrated with patient Julia Holmes achieving cancer-free status after 12 weeks of the modified three-drug treatment protocol.
- Medical University of South Carolina researchers have developed genetically engineered regulatory T-cells equipped with chimeric anti-HLA antibody receptors (CHARs) that can precisely target and neutralize antibody-producing B-cells responsible for organ rejection. - The CHAR-Treg approach demonstrated significant efficacy in laboratory tests using cells from dialysis patients with kidney rejection history, dramatically reducing anti-HLA-A2 antibody levels. - This targeted immunosuppression strategy could revolutionize transplant medicine by reducing rejection risk without broadly suppressing the immune system, particularly benefiting pre-sensitized patients who face limited donor organ eligibility. - The research represents the first application of genetically modified immune cell technology to suppress rather than stimulate immune responses in the context of organ transplantation.
- Biologic eye drops made from patients' own blood serum and amniotic fluid are currently under investigation as novel dry eye treatments that provide essential proteins, vitamins, and growth factors. - Advanced drug delivery systems including slow-release implants and medicated contact lenses are being developed to improve treatment convenience and consistency for dry eye patients. - Neuromodulation approaches, including nasal sprays that stimulate tear production through nerve pathways, represent a new frontier in dry eye therapy currently entering clinical evaluation.
• LiveKidney has enrolled the first patient in a Phase I/IIa clinical trial evaluating LK-SC001, a subcutaneous UC-MSC therapy, for lupus nephritis and systemic lupus erythematosus at the Medical University of South Carolina. • The investigational therapy utilizes umbilical cord-derived mesenchymal stromal cells in a proprietary hydrogel formulation designed to release immunomodulatory compounds that may improve kidney function and reduce inflammation. • Current lupus treatments are effective in only 40% of patients, highlighting the significant unmet need that LK-SC001 aims to address through its novel mechanism targeting the complex immunological nature of the disease.
